Transgenic expression of human thrombomodulin inhibits HMGB1-induced porcine aortic endothelial cell activation

Transplantation

Volumn 100, Issue 9, 2016, Pages 1871-1879

  Bongoni, Anjan K ^a   Klymiuk, Nikolai ^b   Wolf, Eckhard ^b   Ayares, David ^c   Rieben, Robert ^d   Cowan, Peter J ^a,e  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MUNICH   (Germany)

^c REVIVICOR INC   (United States)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CELL ADHESION MOLECULE; CELL SURFACE MARKER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN LIKE PROTEIN 2; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; CYTOKINE; THBD PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; ASSAY; CELL ACTIVATION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; FUNCTIONAL ASSAY; GENE EXPRESSION; HUMAN; NONHUMAN; PORCINE AORTIC ENDOTHELIAL CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TRANSGENIC PIG; WESTERN BLOTTING; WILD TYPE; ANIMAL; AORTA; BLOOD CLOTTING; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; GENOTYPE; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHENOTYPE; PIG; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; AORTA; BIOMARKERS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; CELLS, CULTURED; CYTOKINES; ENDOTHELIAL CELLS; GENOTYPE; HMGB1 PROTEIN; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; PHENOTYPE; PROTEIN INTERACTION DOMAINS AND MOTIFS; SIGNAL TRANSDUCTION; SWINE; THROMBOMODULIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84963603736     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001188     Document Type: Article

References (19)

1. Ekser B, Ezzelarab M, Hara H, et al. Clinical xenotransplantation: The next medical revolution? Lancet. 2012;379:672-683.
2. Roussel JC, Moran CJ, Salvaris EJ, et al. Pig thrombomodulin binds human thrombin but is a poor cofactor for activation of human protein C and TAFI. Am J Transplant. 2008;8:1101-1112.
3. Wuensch A, Baehr A, Bongoni AK, et al. Regulatory sequences of the porcine THBD gene facilitate endothelial-specific expression of bioactive human thrombomodulin in single- And multitransgenic pigs. Transplantation. 2014;97:138-147.
4. Iwase H, Ekser B, Satyananda V, et al. Pig-to-baboon heterotopic heart transplantation-exploratory preliminary experience with pigs transgenic for human thrombomodulin and comparison of three costimulation blockade-based regimens. Xenotransplantation. 2015;22:211-220.
5. Shi CS, Shi GY, Hsiao HM, et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood. 2008;112: 3661-3670.
6. Ito T, Maruyama I. Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost. 2011;9(Suppl 1): 168-173.
7. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418:191-195.
8. Yang H, Wang H, Czura CJ, et al. The cytokine activity of HMGB1. J Leukoc Biol. 2005;78:1-8.
9. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331-342.
10. Wang H, Yang H, Czura CJ, et al. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med. 2001;164(10 Pt 1): 1768-1773.
11. Musumeci D, Roviello GN, Montesarchio D. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacol Ther. 2014;141:347-357.
12. Huang Y, Yin H, Han J, et al. Extracellular hmgb1 functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection. Am J Transplant. 2007;7:799-808.
13. Li JH, Zhao B, Zhu XH, et al. Blockade of extracellular HMGB1 suppresses xenoreactive B cell responses and delays acute vascular xenogeneic rejection. Am J Transplant. 2015;15:2062-2074.
14. Banz Y, Cung T, Korchagina EY, et al. Endothelial cell protection and complement inhibition in xenotransplantation: A novel in vitro model using whole blood. Xenotransplantation. 2005;12:434-443.
15. Li YH, Kuo CH, Shi GY, et al. The role of thrombomodulin lectin-like domain in inflammation. J Biomed Sci. 2012;19:34.
16. Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 2005;115:1267-1274.
17. Miwa Y, Yazaki S, Iwamoto M, et al. Functional difference between membrane-bound and soluble human thrombomodulin. Transplantation. 2015;99:702-709.
18. Ito T, Kawahara K, Okamoto K, et al. Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol. 2008;28:1825-1830.
19. Wu HL, Lin CI, Huang YL, et al. Lysophosphatidic acid stimulates thrombomodulin lectin-like domain shedding in human endothelial cells. Biochem Biophys Res Commun. 2008;367:162-168.